Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis

R. Sari Motlagh, K. Mori, N. Miura, F. Quhal, A. Aydh, E. Laukhtina, B. Pradere, PI. Karakiewicz, DV. Enikeev, M. Deuker, SF. Shariat

. 2021 ; 127 (2) : 143-152. [pub] 20200812

Language English Country Great Britain

Document type Journal Article, Meta-Analysis, Systematic Review

Persistent link   https://www.medvik.cz/link/bmc21019307

OBJECTIVES: To evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU). METHODS: We conducted a systematic review and meta-analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to the I2 statistic, respectively. RESULTS: Nine retrospective and three clinical trial studies were selected after considering inclusion and exclusion criteria. We conducted the meta-analysis on retrospective and randomised controlled trials (RCTs) separately. Eight retrospective and three RCT studies were included to assess the BN/PU recurrence risk and the summarised risk ratio (RR) was 1.02 (95% confidence interval [CI] 0.74-1.41) and 0.93 (95% CI 0.47-1.84), respectively. Five retrospective and two RCT studies were included to assess the progression risk and the summarised RR was 0.91 (95% CI 0.56-1.48) and 1.16 (95% CI 0.30-4.51), respectively. Eight retrospective and three RCT studies were included to assess the whole bladder recurrence risk and the summarised RR was 0.87 (95% CI 0.78-0.97) and 0.89 (95% CI 0.65-1.21), respectively. CONCLUSION: We did not observe any increased risk of total bladder recurrence, BN/PU recurrence, or progression after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019307
003      
CZ-PrNML
005      
20210830100857.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.15146 $2 doi
035    __
$a (PubMed)32564458
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Sari Motlagh, Reza $u Department of Urology, Medical University of Vienna, Vienna, Austria
245    14
$a The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis / $c R. Sari Motlagh, K. Mori, N. Miura, F. Quhal, A. Aydh, E. Laukhtina, B. Pradere, PI. Karakiewicz, DV. Enikeev, M. Deuker, SF. Shariat
520    9_
$a OBJECTIVES: To evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU). METHODS: We conducted a systematic review and meta-analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to the I2 statistic, respectively. RESULTS: Nine retrospective and three clinical trial studies were selected after considering inclusion and exclusion criteria. We conducted the meta-analysis on retrospective and randomised controlled trials (RCTs) separately. Eight retrospective and three RCT studies were included to assess the BN/PU recurrence risk and the summarised risk ratio (RR) was 1.02 (95% confidence interval [CI] 0.74-1.41) and 0.93 (95% CI 0.47-1.84), respectively. Five retrospective and two RCT studies were included to assess the progression risk and the summarised RR was 0.91 (95% CI 0.56-1.48) and 1.16 (95% CI 0.30-4.51), respectively. Eight retrospective and three RCT studies were included to assess the whole bladder recurrence risk and the summarised RR was 0.87 (95% CI 0.78-0.97) and 0.89 (95% CI 0.65-1.21), respectively. CONCLUSION: We did not observe any increased risk of total bladder recurrence, BN/PU recurrence, or progression after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone.
650    _2
$a cystektomie $x škodlivé účinky $7 D015653
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lokální recidiva nádoru $x diagnóza $7 D009364
650    _2
$a hyperplazie prostaty $x diagnóza $x chirurgie $7 D011470
650    _2
$a transuretrální resekce prostaty $x škodlivé účinky $7 D020728
650    _2
$a močový měchýř $x diagnostické zobrazování $7 D001743
650    _2
$a nádory močového měchýře $x diagnóza $x chirurgie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
700    1_
$a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria $u King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Aydh, Abdulmajeed $u Department of Urology, Medical University of Vienna, Vienna, Austria $u King Faisal Medical City, Abha, Saudi Arabia
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Hospital of Tours, Tours, France
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada
700    1_
$a Enikeev, Dmitry V $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Deuker, Marina $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Weil Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan $u European Association of Urology Research Foundation, Arnhem, The Netherlands
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 127, č. 2 (2021), s. 143-152
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32564458 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100858 $b ABA008
999    __
$a ok $b bmc $g 1690189 $s 1139753
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 127 $c 2 $d 143-152 $e 20200812 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20210728
Back

Find record

Citation metrics

Archiving options